XML 40 R12.htm IDEA: XBRL DOCUMENT
v3.25.2

INTANGIBLE ASSETS | 12 Months Ended
--- | ---
Mar. 31, 2025
Intangible Assets [Abstract] |
INTANGIBLE ASSETS | INTANGIBLE ASSETS
| IP Research & Development | Patents | License | Software | Total
Cost | $ | $ | $ | $ | $
Balance as at March 31, 2023 | 3,076 |  | 978 |  | 1,379 |  | 74 |  | 5,507 |
Acquisition of Small Pharma | 29,339 |  | — |  | — |  | — |  | 29,339 |
Additions | — |  | 689 |  | — |  | — |  | 689 |
Effect of foreign exchange | 25 |  | 1 |  | 2 |  | — |  | 28 |
Balance as at March 31, 2024 | 32,440 |  | 1,668 |  | 1,381 |  | 74 |  | 35,563 |
Additions | — |  | 1,931 |  | — |  | — |  | 1,931 |
Effect of foreign exchange | 3,411 |  | 195 |  | 84 |  | — |  | 3,690 |
Balance as at March 31, 2025 | 35,851 |  | 3,794 |  | 1,465 |  | 74 |  | 41,184 |
Accumulated Amortization |  |  |  |  |
Balance as at March 31, 2023 | — |  | — |  | 19 |  | 18 |  | 37 |
Amortization charge | — |  | — |  | 37 |  | 24 |  | 61 |
Balance as at March 31, 2024 | — |  | — |  | 56 |  | 42 |  | 98 |
Amortization charge | — |  | — |  | 39 |  | 26 |  | 65 |
Effect of foreign exchange | — |  | — |  | 3 |  | — |  | 3 |
Balance as at March 31, 2025 | — |  | — |  | 98 |  | 68 |  | 166 |
Net book value as at March 31, 2024 | 32,440 |  | 1,668 |  | 1,325 |  | 32 |  | 35,465 |
Net book value as at March 31, 2025 | 35,851 |  | 3,794 |  | 1,367 |  | 6 |  | 41,018 |
IP Research & Development Refer to note 4 for information on the Small Pharma Acquisition. Patents Costs associated with patent procurement. Impairment The Company performed its annual impairment test of intangible assets not yet in use at March 31, 2025. The recoverable amount was determined based on the relief from royalty method to arrive at the value-in-use (“VIU”). The Company considered an estimate of future revenues and a reasonable royalty rate to apply to financial projections based on the current budget and future commercialization plans. In assessing the VIU, estimated future cash flows are discounted to their present value using a discount rate that reflects the assessment of royalty and business opportunities and risk as well as the market potential. The VIU calculations were performed using a pre-tax discount rate of 20.3% (2024 - 15.7%) and an estimated useful life of 15 year s (2024 - 15 years). Based on the Company’s assessment, the recoverable amount is higher than the carrying value and therefore no impairment loss was recorded for the years ended March 31, 2025 or 2024.

X
- Definition Intangible Assets [Abstract] + References No definition available. + Details
Name: | cybn_IntangibleAssetsAbstract
Namespace Prefix: | cybn_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The entire disclosure for intangible assets. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Name IAS -Number 38 -IssueDate 2024-01-01 -Section Disclosure -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2024-en-r&doctype=Standard&dita_xref=IAS38_g118-128_TI -URIDate 2024-03-27 + Details
Name: | ifrs-full_DisclosureOfIntangibleAssetsExplanatory
Namespace Prefix: | ifrs-full_
Data Type: | dtr-2022:textBlockItemType
Balance Type: | na
Period Type: | duration